Abstract
n-3 polyunsaturated fatty acids (PUFA) have been proposed as potential treatments for human heart failure. The cardioprotective effects of n-3 PUFA are supported by extensive cell culture, animal and human studies. Animal studies with n-3 PUFA have shown marked improvements in many independent risk factors for heart failure, including obesity, type II diabetes, insulin resistance, hypertension and inflammation. However, the evidence from observational studies, randomised controlled trials and meta-analyses that these benefits on risk factors lead to improvements in the symptoms of heart failure in patients is much less convincing. Further, most studies have used marine n-3 PUFA; the role of the plant-derived PUFA, α-linolenic acid (ALA), is even less clear. This discontinuity of scientific evidence from animal to human studies suggests that future studies should focus on defining the optimal dosage range and the efficacy of n-3 PUFA compared to standard treatments using standardised study designs. Further studies on ALA would seem justified.
Keywords: Alpha-linolenic acid, docosahexaenoic acid, eicosapentaenoic acid, heart failure, omega-3 fatty acids.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:The Role of n-3 Polyunsaturated Fatty Acids in Human Heart Failure
Volume: 13 Issue: 1
Author(s): Hemant Poudyal and Lindsay Brown
Affiliation:
Keywords: Alpha-linolenic acid, docosahexaenoic acid, eicosapentaenoic acid, heart failure, omega-3 fatty acids.
Abstract: n-3 polyunsaturated fatty acids (PUFA) have been proposed as potential treatments for human heart failure. The cardioprotective effects of n-3 PUFA are supported by extensive cell culture, animal and human studies. Animal studies with n-3 PUFA have shown marked improvements in many independent risk factors for heart failure, including obesity, type II diabetes, insulin resistance, hypertension and inflammation. However, the evidence from observational studies, randomised controlled trials and meta-analyses that these benefits on risk factors lead to improvements in the symptoms of heart failure in patients is much less convincing. Further, most studies have used marine n-3 PUFA; the role of the plant-derived PUFA, α-linolenic acid (ALA), is even less clear. This discontinuity of scientific evidence from animal to human studies suggests that future studies should focus on defining the optimal dosage range and the efficacy of n-3 PUFA compared to standard treatments using standardised study designs. Further studies on ALA would seem justified.
Export Options
About this article
Cite this article as:
Poudyal Hemant and Brown Lindsay, The Role of n-3 Polyunsaturated Fatty Acids in Human Heart Failure, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/1871530311313010013
DOI https://dx.doi.org/10.2174/1871530311313010013 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Investigating the Practices of Patients and Hospitals in Treatment of Diabetes - A Survey Questionnaire for Arabic Speaking Countries
Current Diabetes Reviews Editorial [Hot Topic: Non-Reproductive Effects of Sex Steroids: Their Immunoregulatory Role (Guest Editor: Jorge Morales-Monto)]
Current Topics in Medicinal Chemistry Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology Modulation of Potassium Channels as a Therapeutic Approach
Current Pharmaceutical Design Subject Index To Volume 4
Current Vascular Pharmacology Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues
Current Medicinal Chemistry The Overlap Between Binge Eating Behaviors and Polycystic Ovarian Syndrome: An Etiological Integrative Model
Current Pharmaceutical Design Oxidative stress and Parkinson’s disease: New hopes in treatment with herbal antioxidants
Current Pharmaceutical Design Assessing Systemic Arterial Hypertension Through Echocardiography: A Review for the Clinician
Current Hypertension Reviews Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Current Drug Targets Cellular and Functional Effects of Insulin Based Therapies and Exercise on Endothelium
Current Pharmaceutical Design Tetracyclic Triterpenoids in Herbal Medicines and their Activities in Diabetes and its Complications
Current Topics in Medicinal Chemistry The Fixed Combination Efficacy Assessment in Patients with Secondary Neovascular Glaucoma and Diabetes Mellitus
Current Diabetes Reviews Molecular Mechanisms of Impaired Endothelial Function Associated with Insulin Resistance
Current Drug Targets - Cardiovascular & Hematological Disorders Low Activity of Plasminogen Activator: A Common Feature of Non- Iatrogenic Comorbidities of Schizophrenia
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Experimental Models for the Study of Drugs Used to Prevent and Treat Vascular Diseases (Executive Editors: C.S. Thompson, D.P. Mikhailidis and K.I. Paraskevas)]
Current Pharmaceutical Design Genetic Aspects of Lone Atrial Fibrillation: What Do We Know?
Current Pharmaceutical Design Phenotypic Screening for Pharmaceuticals Using Tissue Constructs
Current Pharmaceutical Biotechnology Angiotensin-Receptor Blockers and the Risk of Alzheimer´s Disease: A Meta-analysis
Current Reviews in Clinical and Experimental Pharmacology Endothelin Receptor Antagonists: A New Therapeutic Option for Improving the Outcome after Solid Organ Transplantation?
Current Vascular Pharmacology